Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE; VX14-661-110 study group. Flume PA, et al. Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10. Lancet Respir Med. 2021. PMID: 33581080
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability, and efficacy of tezacaftor-ivacaftor in participants aged 12 years or older with cystic fibrosis who were homozygous or heterozygous for t …
Here, we present results of study 661-110 (EXTEND), a 96-week open-label extension study that assessed long-term safety, tolerability …
Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial.
Heubi JE, Schaeffer D, Ahrens RC, Sollo N, Strausbaugh S, Graff G, Jain R, Witte S, Forssmann K. Heubi JE, et al. Among authors: ahrens rc. J Pediatr. 2016 Sep;176:156-161.e1. doi: 10.1016/j.jpeds.2016.05.049. Epub 2016 Jun 11. J Pediatr. 2016. PMID: 27297209 Clinical Trial.
The novel microbial lipase NM-BL was safe and effective in this short term trial. The trial provided clinical proof-of-concept for this novel microbial lipase as a treatment for EPI in CF. ...
The novel microbial lipase NM-BL was safe and effective in this short term trial. The trial provided clinical proof-of-concept for th …
1α,25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer's disease.
Durk MR, Han K, Chow EC, Ahrens R, Henderson JT, Fraser PE, Pang KS. Durk MR, et al. Among authors: ahrens r. J Neurosci. 2014 May 21;34(21):7091-101. doi: 10.1523/JNEUROSCI.2711-13.2014. J Neurosci. 2014. PMID: 24849345 Free PMC article.
We demonstrate a role of the vitamin D receptor (VDR) in reducing cerebral soluble and insoluble amyloid-beta (Abeta) peptides. Short-term treatment of two human amyloid precursor protein-expressing models, Tg2576 and TgCRND8 mice, with 1alpha,25-dihydroxyvitamin D3 [1,25( …
We demonstrate a role of the vitamin D receptor (VDR) in reducing cerebral soluble and insoluble amyloid-beta (Abeta) peptides. Short-ter …
Long term effects of denufosol tetrasodium in patients with cystic fibrosis.
Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB; TIGER-2 Study Investigator Group. Ratjen F, et al. J Cyst Fibros. 2012 Dec;11(6):539-49. doi: 10.1016/j.jcf.2012.05.003. Epub 2012 Jun 8. J Cyst Fibros. 2012. PMID: 22682898 Free article. Clinical Trial.
Long-term intersession variability for single-breath diffusing capacity.
Hegewald MJ, Jensen RL, Teeter JG, Wise RA, Riese RJ, England RD, Ahrens RC, Crapo RO, MacIntyre NR. Hegewald MJ, et al. Among authors: ahrens rc. Respiration. 2012;84(5):377-84. doi: 10.1159/000334699. Epub 2011 Dec 31. Respiration. 2012. PMID: 22213782 Free article.
BACKGROUND: Characterizing long-term diffusing capacity (DL(CO)) variability is important in assessing quality control for DL(CO) equipment and patient management. Long-term DL(CO) variability has not been reported. OBJECTIVES: It was the aim of this study to charac …
BACKGROUND: Characterizing long-term diffusing capacity (DL(CO)) variability is important in assessing quality control for DL(CO) equ …
Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.
Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis; North American Scientific Advisory Group for ESCF. Schechter MS, et al. J Pediatr. 2009 Nov;155(5):634-9.e1-4. doi: 10.1016/j.jpeds.2009.04.059. Epub 2009 Jul 16. J Pediatr. 2009. PMID: 19608199 Free PMC article.
Intersession variability in single-breath diffusing capacity in diabetics without overt lung disease.
Drummond MB, Schwartz PF, Duggan WT, Teeter JG, Riese RJ, Ahrens RC, Crapo RO, England RD, Macintyre NR, Jensen RL, Wise RA. Drummond MB, et al. Among authors: ahrens rc. Am J Respir Crit Care Med. 2008 Aug 1;178(3):225-32. doi: 10.1164/rccm.200801-090OC. Epub 2008 May 8. Am J Respir Crit Care Med. 2008. PMID: 18467511 Free PMC article.
RATIONALE: American Thoracic Society guidelines state that a 10% or greater intersession change in diffusing capacity of the lung (DL(CO)) should be considered clinically significant. However, little is known about the short-term intersession variability in DL(CO) in untra …
RATIONALE: American Thoracic Society guidelines state that a 10% or greater intersession change in diffusing capacity of the lung (DL(CO)) s …
Safety and preliminary clinical activity of a novel pancreatic enzyme preparation in pancreatic insufficient cystic fibrosis patients.
Borowitz D, Goss CH, Stevens C, Hayes D, Newman L, O'Rourke A, Konstan MW, Wagener J, Moss R, Hendeles L, Orenstein D, Ahrens R, Oermann CM, Aitken ML, Mahl TC, Young KR Jr, Dunitz J, Murray FT. Borowitz D, et al. Among authors: ahrens r. Pancreas. 2006 Apr;32(3):258-63. doi: 10.1097/01.mpa.0000202952.10612.21. Pancreas. 2006. PMID: 16628080 Clinical Trial.
At the other dosing levels, the mean coefficient of fat and nitrogen absorption increases were 19.1% +/- 24.9% and 17.8% +/- 13.6%, respectively, whereas the mean stool weight decreased by 517 +/- 362 g. CONCLUSIONS: TCT was well tolerated in this short-term exposure study …
At the other dosing levels, the mean coefficient of fat and nitrogen absorption increases were 19.1% +/- 24.9% and 17.8% +/- 13.6%, respecti …
Aerosol delivery and safety of recombinant human deoxyribonuclease in young children with cystic fibrosis: a bronchoscopic study. Pulmozyme Pediatric Broncoscopy Study Group.
Wagener JS, Rock MJ, McCubbin MM, Hamilton SD, Johnson CA, Ahrens RC. Wagener JS, et al. Among authors: ahrens rc. J Pediatr. 1998 Oct;133(4):486-91. doi: 10.1016/s0022-3476(98)70055-1. J Pediatr. 1998. PMID: 9787685 Clinical Trial.
The purpose of this study was to assess the delivery to the lungs and the short-term safety of recombinant human deoxyribonuclease (rhDNase, Pulmozyme) in children with cystic fibrosis younger than 5 years of age compared with older children. ...During this time adverse ev …
The purpose of this study was to assess the delivery to the lungs and the short-term safety of recombinant human deoxyribonuclease (r …
Albuterol: an adrenergic agent for use in the treatment of asthma pharmacology, pharmacokinetics and clinical use.
Ahrens RC, Smith GD. Ahrens RC, et al. Pharmacotherapy. 1984 May-Jun;4(3):105-21. doi: 10.1002/j.1875-9114.1984.tb03330.x. Pharmacotherapy. 1984. PMID: 6739311
Regularly scheduled administration of albuterol by metered-dose inhaler is a widely used and effective maintenance medication for patients requiring long-term prophylactic therapy. However comparisons of the ability of this regimen and the other common maintenance regimens …
Regularly scheduled administration of albuterol by metered-dose inhaler is a widely used and effective maintenance medication for patients r …
11 results